Cargando…

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis

BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Post‐marketing surveillance (PMS) is an important part of monitoring adverse events (AEs). AIMS: To report an analysis of PMS case safety reports for tofacitinib in patients with UC METHODS: World...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rubin, David T., Modesto, Irene, Vermeire, Séverine, Danese, Silvio, Ng, Siew C., Kwok, Kenneth K., Koram, Nana, Jones, Thomas V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Post‐marketing Safety of Tofacitinib in Ulcerative Colitis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293472/ https://www.ncbi.nlm.nih.gov/pubmed/34626429 http://dx.doi.org/10.1111/apt.16619

Ejemplares similares

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Effectiveness and safety of tofacitinib for ulcerative colitis: two‐year results of the ICC Registry
por: Straatmijer, Tessa, et al.
Publicado: (2022)

Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open‐label, long‐term extension study, OCTAVE open
por: Panaccione, Remo, et al.
Publicado: (2022)

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment
por: Sandborn, William J., et al.
Publicado: (2021)

Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions
por: van den Broek, F J C, et al.
Publicado: (2008)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

The effectiveness and safety of infliximab compared with biosimilar CT‐P13, in 3112 patients with ulcerative colitis
por: Meyer, Antoine, et al.
Publicado: (2019)

Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
por: Osterman, Mark T., et al.
Publicado: (2019)

Intestinal ultrasound detects an increased diameter and submucosal layer thickness in the appendix of patients with ulcerative colitis compared to healthy controls – a prospective cohort study
por: Reijntjes, Maud A., et al.
Publicado: (2022)

Long‐term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open‐label, 48‐week extension study
por: Panés, Julián, et al.
Publicado: (2019)

Nationwide improvement in outcomes of emergency admission for ulcerative colitis in England, 2005‐2013
por: Shawihdi, Mustafa, et al.
Publicado: (2019)

The taxonomic composition of the donor intestinal microbiota is a major factor influencing the efficacy of faecal microbiota transplantation in therapy refractory ulcerative colitis
por: Kump, P., et al.
Publicado: (2017)

Mucosal 5‐aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis
por: Olaisen, Maya, et al.
Publicado: (2019)

Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice
por: Sedhom, Mamdouh A K, et al.
Publicado: (2013)

TLR-independent anti-inflammatory function of intestinal epithelial TRAF6 signalling prevents DSS-induced colitis in mice
por: Vlantis, Katerina, et al.
Publicado: (2016)

Procreative consciousness in a global market: gay men's paths to surrogacy in the USA
por: Smietana, Marcin
Publicado: (2019)

A limited market: the recruitment of gay men as surrogacy clients by the infertility industry in the USA
por: Jacobson, Heather
Publicado: (2018)

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study
por: Mizokami, Yuji, et al.
Publicado: (2018)

Recent Teaching on Their Surgical Diagnosis and Treatment
Publicado: (1920)

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

TiO(2) suppliers face disappointing demand & find it hard to raise prices
Publicado: (2003)

Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
por: Vermeire, Séverine, et al.
Publicado: (2020)

Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme
por: Schreiber, Stefan, et al.
Publicado: (2023)

Integrated marketing communications : a systems approach /
por: Sirgy, M. Joseph
Publicado: (1998)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials
por: Panés, Julian, et al.
Publicado: (2021)

Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
por: Biedermann, Luc, et al.
Publicado: (2022)

Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme
por: Danese, Silvio, et al.
Publicado: (2020)

The market for acquiring card payments from small and medium-sized Canadian merchants
por: Welte, Angelika, et al.
Publicado: (2021)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Altered microbiota in microscopic colitis
por: Fischer, Hans, et al.
Publicado: (2015)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Low eukaryotic viral richness is associated with faecal microbiota transplantation success in patients with UC
por: Conceição-Neto, Nádia, et al.
Publicado: (2018)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
por: Panés, Julian, et al.
Publicado: (2018)

Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies
por: Panés, Julian, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ce0c8681np1qnnbvrpbkoqrnub